Literature DB >> 14534339

Chronic myeloid leukemia--advances in biology and new approaches to treatment.

John M Goldman1, Junia V Melo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14534339     DOI： 10.1056/NEJMra020777

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  213 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes.

Authors:  Isaac A Klein; Wolfgang Resch; Mila Jankovic; Thiago Oliveira; Arito Yamane; Hirotaka Nakahashi; Michela Di Virgilio; Anne Bothmer; Andre Nussenzweig; Davide F Robbiani; Rafael Casellas; Michel C Nussenzweig
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

3.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 4.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

5.  Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.

Authors:  Sandra C Dos Santos; Nuno P Mira; Ana S Moreira; Isabel Sá-Correia
Journal:  OMICS       Date:  2012-07-09

6.  LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.

Authors:  Baoming He; Ying Bai; Wei Kang; Xiaoping Zhang; Xiaojian Jiang
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.

Authors:  Jana Portnow; Behnam Badie; Susan Markel; An Liu; Massimo D'Apuzzo; Paul Frankel; Rahul Jandial; Timothy W Synold
Journal:  Eur J Cancer       Date:  2013-02-04       Impact factor: 9.162

8.  Fluorescent in situ hybridization analysis of Philadelphia chromosome-negative chronic myeloid leukemia with the bcr/abl fusion gene.

Authors:  Fumihiko Monma; Kazuhiro Nishii; Shunji Yamamori; Noboru Hosokai; Takahiro Nakazaki; Felipe Lorenzo; Eiji Usui; Miho Sakakura; Hiroyuki Miyashita; Atsushi Fujieda; Kohshi Ohishi; Naoyuki Katayama; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

9.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Authors:  Tom Lenaerts; Jorge M Pacheco; Arne Traulsen; David Dingli
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

Review 10.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.